Peptide record

TPDB27167

Antibacterial Anticancer Antifungal Antiviral Toxicity modified_plain modified
3 source-reported length (unverified)
Basic Information
TPDB27167
Antibacterial Anticancer Antifungal Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CAFPdb dbAMP
modified_plain
Yes
A modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide record curated from Peptipedia, CAFPdb, and dbAMP, without an available 3D structural model. Source-reported length: 3 (unverified).
Modified, details unspecified
Sequence
XXX

Source notation is retained verbatim; residue notation and chemical identity have not been independently validated. The displayed length is source-reported and unverified.

Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
3 source-reported length (unverified)
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
Toxicity
25 µg/mL
Cytotoxic
IC50 | 25 | µg/mL | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Human hepatocyte cells HL-7702 (L02)

Source & Reference

NA
DBAASP
Two novel hepatocellular carcinoma cycle inhibitory cyclodepsipeptides from a hydrothermal vent crab-associated fungus Aspergillus clavatus C2WU. | Mar Drugs | 2013
Evidence 2 Activity

Activity

10% Killing
Toxicity
40 µg/mL
Cytotoxic
10% Killing | 40 | µg/mL | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Zn-driven discovery of a hydrothermal vent fungal metabolite clavatustide C, and an experimental study of the anti-cancer mechanism of clavatustide B. | Mar Drugs | 2014
Evidence 3 Activity

Activity

IC50
Toxicity
>30 µM
Cytotoxic
IC50 | >30 | µM | target cell: Human gastric epithelial cells GES-1

Target

Human gastric epithelial cells GES-1

Source & Reference

NA
DBAASP
Antibacterial Cyclic Tripeptides from Antarctica-Sponge-Derived Fungus Aspergillus insulicola HDN151418. | Mar Drugs | 2020
Evidence 4 Activity

Activity

IC50
Toxicity
>30 µM
Cytotoxic
IC50 | >30 | µM | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Human hepatocyte cells HL-7702 (L02)

Source & Reference

NA
DBAASP
Antibacterial Cyclic Tripeptides from Antarctica-Sponge-Derived Fungus Aspergillus insulicola HDN151418. | Mar Drugs | 2020
Evidence 5 Activity

Activity

50% Hemolysis
Toxicity
>1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013
Evidence 6 Activity

Activity

50% Hemolysis
Toxicity
1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
750 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 750 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013
Evidence 8 Activity

Activity

50% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. | Chem Biol Drug Des | 2013